Trials / Completed
CompletedNCT02679235
Brain Energy and Aging With Triheptanoin
Brain Energy and Aging With Triheptanoin: The BEAT7 Study
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Université de Sherbrooke · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
BEAT7-001 is a single group study (supplementation). Using a multi-modal brain imaging portfolio, this study will assess whether brain energy metabolism (glucose and ketones), structure or functional connectivity change in older people with frontal glucose hypometabolism after 28 days on an oral dose of 1 g/kg/day of triheptanoin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | POST Triheptanoin | The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack. |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2018-08-08
- Completion
- 2018-08-08
- First posted
- 2016-02-10
- Last updated
- 2020-07-23
- Results posted
- 2020-04-15
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02679235. Inclusion in this directory is not an endorsement.